终末期肝病血管活性物抵抗发生机制与诊疗关系的争议和对策  

Vasoactive substance resistance mechanisms in diagnosis and treatment of end-stage liver diseases:Disputes and counter-measurement

作　　者：刘建军[1] 郑文凯[1] 王江红[1] 任燕军 刘研 赵利珍 LIU Jianjun;ZHENG Wenkai;WANG Jianghong;REN Yanjun;LIU Yan;ZHAO Lizhen(Department of Gastroenterology,The Second Hospital of Handan City,Handan,Hebei 056001,China)

机构地区：[1]河北省邯郸市第二医院消化内科,河北邯郸056001

出　　处：《临床肝胆病杂志》2022年第10期2408-2411,共4页Journal of Clinical Hepatology

摘　　要：终末期肝病(ESLD)血管活性物(VS)抵抗是指患者对内、外源性VS反应性和心脏、血管兴奋性降低,周围循环功能障碍及诱发相关不良事件的现象。VS抵抗与ESLD相关并发症的发病机制、诊断和治疗密切相关,但仍存在较多争议问题,包括:(1)ESLD患者发生VS抵抗的原因和机制;(2)VS抵抗与ESLD多器官损伤的关系;(3)如何预防与缓解VS抵抗;(4)ESLD患者发生VS抵抗的血管活性药物使用问题等。本文就上述问题提出商榷,旨在探讨如何防止与缓解ESLD患者VS抵抗以及减少相关不良事件发生。The vasoactive substance resistance(VSR) in the end-stage liver disease(ESLD) refers as the reduction of patients’ responsiveness to endogenous and exogenous vasoactive substances,cardiac and vascular excitability,peripheral circulatory dysfunction,but induction of related adverse events.VSR is closely related to pathogenesis and treatment-related ESLD complications.However,to date,there are so many unsolved issues,like 1).The cause and underlying mechanism of VSR in ESLD patients;2).VSR and ESLD multiple organ damages;3).The preventive and mitigated measurement of VSR;and 4).VSR vasoactive drug use in ESLD patients.This review discussed and summarized the up to date progress in this field of research and clinical VSR in patients with ESLD,i.e.,VRS in ESLD patients,disputes of vasoconstrictor drug therapy in ESLD patients,and future research direction of the field.

关 键 词：终末期肝病 血管收缩药 血管舒张药 

分 类 号：R575[医药卫生—消化系统]